

## Q1 2017: U.S. BILLS IMPACTING PHARMACEUTICAL DRUGS AND BIOLOGIC PRODUCTS

BILL	TOPICS	PARTY	STATUS
<a href="#"><u>H.R. 1776</u></a> ; <a href="#"><u>S. 771</u></a> : Improving Access to Affordable Prescription Drugs Act	Market exclusivity, drug shortages, advertising spend, ANDA settlement practices	(D)	Committee
<a href="#"><u>S. 495</u></a> : Medical Innovation Prize Fund Act	Market exclusivity, awarding innovation	(I)	Committee
<a href="#"><u>H.R. 1245</u></a> ; <a href="#"><u>S. 469</u></a> : Affordable and Safe Prescription Drug Importation Act	Foreign drug importation	(D); (I)	Committee
<a href="#"><u>H.R. 1223</u></a> : The OPEN ACT	Orphan drug exclusivity	(R)	Committee
<a href="#"><u>S. 297</u></a> : Increasing Competition in Pharmaceuticals Act <a href="#"><u>H.R. 749</u></a> : Lower Drug Costs through Competition Act	Drug shortages, REMS programs	(D); (R)	Committee
<a href="#"><u>S. 183</u></a> : Short on Competition Act	Drug shortages	(D)	Committee
<a href="#"><u>S. 124</u></a> : Preserve Access to Affordable Generics Act	ANDA settlement practices	(D)	Committee